Targets › EPHA5
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2026.
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. (UniProt, P54756)
Open in Phaseline: the race on EPHA5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MBrace Therapeutics | MBRC-101 anti-EPHA5 antibody-drug conjugate with monomethyl auristatin E (MMAE) payload | EPHA5 | Phase 1 | Cancer | Nov 2026 |
Cancer (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.